China · Delayed Price · Currency is CNY Jiangsu Yahong Meditech Company Description
Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally.
It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-specific protease 1 (USP1) for the treatment of ovarian and breast cancer; APL-2501 for the treatment of ovarian cancer; AT-018 for the treatment of breast cancer; and AT-021 for the treatment of breast cancer and other solid tumors.
The company also develops APL-1706 and APLD-2304 for non-muscle-invasive bladder cancer (NMIBC) diagnosis and surgery; APL-1202 for Untreated intermediate-risk NMIBC and neoadjuvant therapy before MIBC; and APL-2401 for urinary tumors.
In addition, it develops APL-1202 for the treatment of free-living amoeba infection; APL-1401 for moderate to severe active ulcerative colitis; and APL-2301, an antibiotic for Acinetobacter baumannii infection.
The company was incorporated in 2010 and is based in Shanghai, China.
| Country | China |
| Founded | 2010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 497 |
| CEO | Ke Pan |
Contact Details
Address: Building B, Qiantan World Trade Center Shanghai, 200126 China | |
| Phone | 86 21 6858 3863 |
| Website | asieris.cn |
Stock Details
| Ticker Symbol | 688176 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100005XW0 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ke Pan | Founder, Chairman and Chief Executive Officer |
| Chengfeng Zhuang | Deputy GM and Director |
| Mingyuan Yang | Financial Manager, Board Secretary and Director |
| Baohua Chen | Executive Vice President of Finance |
| Haiyao Hu | Accounting Supervisor |
| Dr. Ningshu Liu | Chief Scientific Officer |
| David Wilson Ph.D. | Senior Vice President of BD |
| Dr. Chen Yu | Senior Vice President of Biological Research, Drug Discovery Division and Head of Translational Medicine Research |
| Yang Zhao | Senior Vice President of Business Development |
| Ying Xu | Chief Business Officer |